NVNO RSI Chart
Last 7 days
-0.2%
Last 30 days
4.0%
Last 90 days
-0.6%
Trailing 12 Months
27.0%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 175.5K | 0 | 0 | 0 |
2023 | 238.0K | 240.0K | 209.0K | 198.5K |
2022 | 20.0K | 54.0K | 122.0K | 161.0K |
2021 | 3.0K | 10.0K | 15.0K | 0 |
2019 | 186.7K | 103.4K | 61.7K | 31.2K |
2018 | 363.2K | 304.3K | 245.4K | 186.6K |
2017 | 0 | 0 | 0 | 422.1K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 13, 2024 | alavi hamed | sold | -51,837 | 6.22 | -8,334 | chief technology officer |
Mar 13, 2024 | alavi hamed | acquired | 29,919 | 3.59 | 8,334 | chief technology officer |
Sep 13, 2022 | jenusaitis matthew | acquired | - | - | 1,041 | - |
Sep 13, 2022 | gray robert | acquired | - | - | 1,041 | - |
Aug 16, 2022 | duhay francis | bought | 47,591 | 6.14 | 7,751 | - |
Jun 30, 2022 | shrivastava sanjay | bought | 3,850 | 3.85 | 1,000 | - |
Jun 27, 2022 | berman robert andrew | bought | 9,500 | 3.8 | 2,500 | chief executive officer |
Nov 30, 2021 | berman robert andrew | acquired | - | - | 200,000 | chief executive officer |
Nov 30, 2021 | glickman marc h. | acquired | - | - | 100,000 | svp & chief medical officer |
Nov 30, 2021 | glynn craig | acquired | - | - | 50,000 | chief financial officer |
Which funds bought or sold NVNO recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | new | - | 137,703 | 137,703 | -% |
May 15, 2024 | MARSHALL WACE, LLP | added | 162 | 139,611 | 218,253 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | added | 14.12 | 42,648 | 247,852 | -% |
May 15, 2024 | KINGDON CAPITAL MANAGEMENT, L.L.C. | reduced | -22.01 | -752,117 | 3,557,050 | 0.39% |
May 15, 2024 | Royal Bank of Canada | reduced | -89.00 | -1,000 | - | -% |
May 15, 2024 | OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | reduced | -4.23 | 16,493 | 1,231,120 | 0.09% |
May 15, 2024 | PERCEPTIVE ADVISORS LLC | unchanged | - | 186,995 | 3,390,830 | 0.06% |
May 15, 2024 | Nantahala Capital Management, LLC | reduced | -64.91 | -4,564,160 | 2,696,800 | 0.15% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 22.48 | 4,336 | 18,970 | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | sold off | -100 | -2,241,040 | - | -% |
Unveiling enVVeno Medical Corporation's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to enVVeno Medical Corporation)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 181.0B | 40.3B | 32.18 | 4.49 | ||||
BDX | 68.3B | 19.7B | 51.24 | 3.46 | ||||
ALGN | 20.4B | 3.9B | 44.2 | 5.22 | ||||
BAX | 18.0B | 14.9B | 6.79 | 1.21 | ||||
MID-CAP | ||||||||
ATR | 9.8B | 3.5B | 31.27 | 2.76 | ||||
HSIC | 9.6B | 12.5B | 24.63 | 0.77 | ||||
BIO | 8.4B | 2.6B | -26.02 | 3.22 | ||||
XRAY | 5.9B | 3.9B | -62.84 | 1.49 | ||||
AXNX | 3.4B | 387.1M | -216.3 | 8.9 | ||||
PDCO | 2.3B | 6.6B | 11.93 | 0.35 | ||||
SMALL-CAP | ||||||||
AHCO | 1.3B | 3.2B | -1.91 | 0.41 | ||||
ANIK | 376.6M | 169.3M | -4.9 | 2.23 | ||||
ANGO | 241.9M | 324.0M | -1.26 | 0.75 | ||||
APYX | 56.1M | 50.5M | -2.46 | 1.11 | ||||
AEMD | 1.0M | 3.7M | -0.09 | 0.28 |
enVVeno Medical Corporation News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q3 | 2021Q2 | 2021Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 |
Revenue | 76.1% | 59.00 | 34.00 | 44.00 | 39.00 | 82.00 | 44.00 | 75.00 | 37.00 | 5.00 | 5.00 | 7.00 | 3.00 | - | - | - | 31.00 | 30.00 | 42.00 | 83.00 | 31.00 | 29.00 |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 31.00 | 30.00 | 42.00 | 83.00 | - | - |
S&GA Expenses | -25.7% | 2,451 | 3,300 | 2,551 | 2,600 | 3,202 | 3,663 | 3,659 | 3,913 | 3,783 | 1,482 | 1,296 | 1,176 | 922 | 1,157 | 1,532 | 1,301 | 1,217 | 1,105 | 2,915 | - | - |
R&D Expenses | 2.5% | 3,052 | 2,979 | 2,798 | 4,214 | 3,595 | 2,797 | 2,492 | 3,073 | 1,552 | 1,225 | 1,090 | 1,632 | 788 | 677 | 428 | 313 | 293 | 425 | 280 | - | - |
Interest Expenses | - | - | - | - | 39.00 | 45.00 | 94.00 | 25.00 | 37.00 | 5.00 | 5.00 | -6.70 | 3.00 | -8.23 | -19.14 | -13.93 | -8.61 | -17.28 | -6.98 | 112 | 210 | - |
Net Income | 11.6% | -4,992 | -5,649 | -5,001 | -6,474 | -6,392 | -6,180 | -6,097 | -7,062 | -5,330 | -2,389 | -2,378 | -2,773 | -2,290 | -1,814 | -1,946 | -1,573 | -1,781 | -1,468 | -5,045 | - | - |
Net Income Margin | -6.4% | -126.02* | -118.47* | -115.06* | -104.76* | -108.11* | -153.22* | -225.22* | -440.17* | -954.25* | -794.27* | -1.15 | -3.58 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 28.5% | -3,559 | -4,977 | -4,216 | -4,584 | -5,114 | -3,865 | -4,497 | -3,982 | -3,390 | -2,385 | -2,798 | -3,866 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -7.8% | 44,829 | 48,635 | 28,094 | 32,086 | 36,613 | 41,661 | 45,456 | 49,932 | 54,224 | 57,699 | 59,172 | 42,352 | 45,055 | 10,538 | 7,043 | 3,733 | 2,770 | 3,434 | 5,751 | 7,253 | 5,488 |
Current Assets | -7.8% | 43,248 | 46,923 | 26,217 | 30,108 | 34,519 | 39,436 | 40,708 | 37,760 | 51,650 | 55,040 | 58,207 | 41,439 | 44,166 | 9,569 | 5,978 | 1,785 | 840 | 1,424 | 3,060 | 4,630 | 2,946 |
Cash Equivalents | -36.1% | 2,314 | 3,620 | 4,946 | 4,700 | 2,273 | 4,555 | 2,895 | 9,070 | 51,338 | 54,728 | 57,897 | 41,039 | 43,837 | 9,335 | 5,629 | 1,564 | 720 | 1,307 | 2,943 | 4,465 | 2,753 |
Net PPE | -13.5% | 289 | 334 | 385 | 438 | 472 | 521 | 566 | 606 | 635 | 618 | 599 | 490 | 395 | 399 | 426 | 427 | 330 | 344 | 350 | 194 | 25.00 |
Liabilities | 1.0% | 2,460 | 2,435 | 3,179 | 3,274 | 2,484 | 2,932 | 2,785 | 3,374 | 2,907 | 3,295 | 1,118 | 1,478 | 2,043 | 3,440 | 2,248 | 3,364 | 2,784 | 2,444 | 2,667 | 2,601 | 2,623 |
Current Liabilities | 8.5% | 1,487 | 1,371 | 2,031 | 2,067 | 1,167 | 1,530 | 1,304 | 1,816 | 1,270 | 1,580 | 1,118 | 1,393 | 1,874 | 3,186 | 1,915 | 2,953 | 2,253 | 1,876 | 2,016 | 1,883 | 1,839 |
Shareholder's Equity | -8.3% | 42,369 | 46,200 | 24,915 | 28,812 | 34,129 | 38,729 | 42,671 | 46,558 | 51,317 | 54,404 | 58,055 | 40,874 | 43,012 | 7,098 | 4,795 | 369 | - | 990 | 3,084 | 4,652 | 2,865 |
Retained Earnings | -3.8% | -135,028 | -130,036 | -124,387 | -119,386 | -112,912 | -106,520 | -100,340 | -94,243 | -87,181 | -81,851 | -72,863 | -70,474 | -68,096 | -65,323 | -60,949 | -58,974 | -57,347 | -56,187 | -53,897 | -52,082 | -50,136 |
Additional Paid-In Capital | 0.7% | 177,397 | 176,236 | 149,302 | 148,198 | 147,041 | 145,249 | 143,011 | 140,801 | 138,498 | 136,255 | 130,918 | 111,348 | 111,108 | 72,421 | 65,744 | 59,344 | 57,333 | 57,178 | 56,981 | 56,734 | 53,001 |
Shares Outstanding | 0.1% | 13,330 | 13,317 | 9,472 | 9,472 | 9,472 | 9,472 | 11,229 | 11,229 | 11,229 | 9,470 | 9,180 | 8,514 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 29,200 | - | - | - | 35,800 | - | - | - | 58,500 | - | - | - | 9,244 | - | - | - | 18,639 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 28.6% | -3,549 | -4,973 | -4,213 | -4,563 | -5,109 | -3,856 | -4,483 | -3,959 | -3,321 | -3,102 | -2,233 | -2,671 | -3,842 | -2,613 | -2,591 | -1,319 | -1,152 | -1,623 | -1,350 | -1,429 | -1,493 |
Share Based Compensation | -2.5% | 1,115 | 1,144 | 1,103 | 1,157 | 1,792 | 2,238 | 2,210 | 2,303 | 2,243 | 5,343 | 325 | 202 | 129 | 518 | 194 | 38.00 | 131 | - | 194 | 447 | 104 |
Cashflow From Investing | 109.9% | 2,197 | -22,144 | 4,445 | 7,004 | 2,827 | 5,516 | -1,692 | -38,309 | -69.00 | -65.00 | -152 | -127 | -24.00 | -27.54 | -24.96 | -122 | -5.31 | -12.96 | -171 | -177 | -1.80 |
Cashflow From Financing | - | 46.00 | - | - | - | - | - | - | - | - | -4.00 | 19,243 | - | 38,368 | 6,347 | 5,872 | 2,286 | 570 | - | - | 3,320 | 2,317 |
Condensed Statements Of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating Expenses: | ||
Research and development expenses | $ 3,052 | $ 3,595 |
Selling, general and administrative expenses | 2,451 | 3,202 |
Loss from Operations | (5,503) | (6,797) |
Other Income: | ||
Realized gain from sales of trading securities | 408 | 82 |
Unrealized gain from trading securities | 44 | 278 |
Interest income, net | 59 | 45 |
Total Other Income | 511 | 405 |
Net Loss | $ (4,992) | $ (6,392) |
Net Loss Per Basic Common Share: | $ (0.31) | $ (0.57) |
Net Loss Per Diluted Common Share: | $ (0.31) | $ (0.57) |
Weighted Average Number of Common Shares Outstanding: | ||
Basic | 16,057 | 11,231 |
Diluted | 16,057 | 11,231 |
Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 2,314 | $ 3,620 |
Short-term investments | 40,628 | 42,792 |
Prepaid expenses and other current assets | 306 | 511 |
Total Current Assets | 43,248 | 46,923 |
Property and equipment, net | 289 | 334 |
Operating lease right-of-use assets, net | 1,261 | 1,347 |
Security deposits and other assets | 31 | 31 |
Total Assets | 44,829 | 48,635 |
Current Liabilities: | ||
Accounts payable, accrued expenses and other current liabilities | 1,143 | 1,033 |
Current portion of operating lease liabilities | 344 | 338 |
Total Current Liabilities | 1,487 | 1,371 |
Long-term operating lease liabilities | 973 | 1,064 |
Total Liabilities | 2,460 | 2,435 |
Commitments and Contingencies | ||
Stockholders’ Equity: | ||
Preferred stock, par value $0.00001, 10,000 shares authorized: no shares issued or outstanding | ||
Common stock, par value $0.00001, 250,000 shares authorized, 13,330 and 13,317 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | ||
Additional paid-in capital | 177,397 | 176,236 |
Accumulated deficit | (135,028) | (130,036) |
Total Stockholders’ Equity | 42,369 | 46,200 |
Total Liabilities and Stockholders’ Equity | $ 44,829 | $ 48,635 |